دورية
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
| العنوان: | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials |
|---|---|
| المؤلفون: | Griffiths, Christopher E M, Reich, Kristian, Lebwohl, Mark, van de Kerkhof, Peter, Paul, Carle, Menter, Alan, Cameron, Gregory S, Erickson, Janelle, Zhang, Lu, Secrest, Roberta J, Ball, Susan, Braun, Daniel K, Osuntokun, Olawale O, Heffernan, Michael P, Nickoloff, Brian J, Papp, Kim |
| المصدر: | The Lancet; August 2015, Vol. 386 Issue: 9993 p541-551, 11p |
| مستخلص: | Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 01406736 1474547X |
|---|---|
| DOI: | 10.1016/S0140-6736(15)60125-8 |